Clinical trial
Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL
NCT00369707 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00369707 |
|---|---|
| Title | Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL |
| Official title | A Phase II Trial of Combination Bortezomib and Rituximab as Front-line Therapy for Low-grade Non-Hodgkin's Lymphoma |
| Lead sponsor | Northwestern University, Other |
| Collaborators | Robert H. Lurie Cancer Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Rituximab, bortezomib |
| Enrollment | 42 |
| Start date | Aug 9, 2006 |
| Primary completion | May 22, 2012 |
| Completion | Oct 10, 2014 |
| First posted | Aug 29, 2006 |
| Last update posted | Sep 6, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: